Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
ELTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Elicio Therapeutics, Inc.NASDAQ: ELTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 18.5% from a year ago
Cash & equivalents stood at $14.95M at the end of Q1 FY2026, down 18.5% from a year earlier and down 19.5% from the prior quarter. Over 3 fiscal years it compounded at +33.5% a year.
Context
- Cash & equivalents amounted to 65.9% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -18.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 18.56M USD
- Year-over-year change
- +5.4%
- 4-year CAGR
- -32.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.56M | +5.4% |
| FY2024 | 2024-12-31 | 17.62M | +36.6% |
| FY2023 | 2023-12-31 | 12.89M | +65.4% |
| FY2022 | 2022-12-31 | 7.8M | -91.2% |
| FY2021 | 2021-12-31 | 88.76M | — |
Cash & Equivalents vs competitors
How ELTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -18.5% is the 7th highest of 9, against a peer median of -3.4%.
- Cash & equivalents amounts to 65.9% of total assets for ELTX, versus a peer median of 22.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 78.53M CHF | -3.5% | -2.0% | 89.9% | |
| Mar 2026 | $71.32M USD | +58.2% | +112.3% | 36.8% | |
| Mar 2026 | $42.15M USD | -3.4% | -30.7% | 27.0% | |
| Mar 2026 | $27.36M USD | -48.0% | +1.9% | 7.4% | |
| Mar 2026 | $26.05M USD | +37.8% | +18.8% | 18.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $14.95M USD | -18.5% | +33.5% | 65.9% |
| Mar 2026 | $9.64M USD | -4.6% | -11.7% | 18.6% | |
| Mar 2026 | $8.54M USD | -64.5% | +2.2% | 17.4% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.13M USD | +109.1% | -13.7% | 91.3% |
| Peer median (excluding ELTX) | — | -3.4% | -0.1% | 22.8% | |
Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 88.76M | 7.8M | 12.89M | 17.62M | 18.56M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 806K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 379K | 36K | 895K | 1.28M | 73K |
| Total Current Assets | 91.25M | 10.72M | 16.35M | 20.69M | 19.31M |
| Property, Plant & Equipment (Net) | 4.44M | 8.5M | 7.28M | 6.19M | 5.08M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 723K | 617K | 0 | 696K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 106K | 2.83M | 3.52M | 600K | 1.47M |
| Total Non-current Assets | 5.27M | 11.95M | 10.8M | 7.49M | 6.55M |
| Total Assets | 96.51M | 22.66M | 27.15M | 28.18M | 25.86M |
| Account Payables | 4.71M | 2.81M | 4.37M | 1.04M | 672K |
| Short-term Debt | 952K | 692K | 0 | 901K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.3M | 1.44M | 0 | 1.17M | 0 |
| Other Current Liabilities | 2.06M | 444K | 2.57M | 2.31M | 2.53M |
| Total Current Liabilities | 11.3M | 6.87M | 9.76M | 11.52M | 8.11M |
| Long-term Debt | 0 | 0 | 0 | 20.03M | 9.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 92K | 11K | 2.83M | 2.62M |
| Total Non-current Liabilities | 3.71M | 6.88M | 6.02M | 27.97M | 16.12M |
| Total Liabilities | 15.01M | 13.75M | 15.77M | 39.49M | 24.23M |
| Common Stock | 300K | 3K | 96K | 110K | 178K |
| Retained Earnings | (215.14M) | (107.01M) | (142.2M) | (194.1M) | (233.67M) |
| Accumulated OCI | (103K) | 0 | (197K) | (175K) | (127K) |
| Other Stockholders Equity | 226.01M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.51M | 8.92M | 11.37M | (11.31M) | 1.64M |
| Total Debt | 4.66M | 7.48M | 6.92M | 26.04M | 14.51M |
| Net Debt | (84.09M) | (316K) | (5.98M) | 8.42M | (4.05M) |
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.